Sanofi (SNY) Expands Rare Disease Reach With $9.5B Blueprint Deal

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making waves for acquiring Blueprint for $9.5 billion.

Sanofi (NASDAQ:SNY), a global biopharmaceutical leader headquartered in France with about 83,000 employees, is focused on immunology, oncology, rare diseases, and vaccines. The company continues to expand its innovative pipeline through internal research and strategic acquisitions.

In June 2025, Sanofi (NASDAQ:SNY) announced its largest deal of the year, a $9.5 billion acquisition of U.S.-based Blueprint Medicines. This strategic move strengthens the company’s position in rare immunological diseases. Blueprint adds to the business’s portfolio Ayvakit/Ayvakyt (avapritinib), the only approved treatment for systemic mastocytosis (SM) in the U.S. and EU, along with promising pipeline assets like elenestinib and BLU-808, both targeting KIT-driven and other immune-related conditions.

The acquisition also enhances the corporation’s reach through Blueprint’s existing relationships with allergists, dermatologists, and immunologists, aligning well with Sanofi (NASDAQ:SNY)’s goal to become a top player in immunology. CEO Paul Hudson called the deal a major step toward building a global immunology powerhouse.

A closeup of pills in a pharmacy, representing the high quality medications of the company.

This move complements the company’s existing success with Dupixent (dupilumab), its flagship immunology drug, recently approved in the U.S. as the first targeted treatment for bullous pemphigoid.

In addition, the business plans to invest at least $20 billion in the U.S. by 2030 to boost R&D, manufacturing, and new medicine launches, supporting growth and improving supply chain resilience.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.